The return of thalidomide: Are birth defects surveillance systems ready?

American Journal of Medical Genetics

Volumn 73, Issue 3, 1997, Pages 251-258

  Yang, Quanhe ^a,c   Khoury, Muin J ^b   James, Levy M ^a   Olney, Richard S ^a   Paulozzi, Len J ^a   Erickson, J David ^a  

^a NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c BDDD   (United States)

Author keywords

Birth defect; Epidemiologic method; Surveillance; Thalidomide

Indexed keywords

THALIDOMIDE;

ARTICLE; BIRTH DEFECT; DRUG MONITORING; HUMAN; LIMB DEFECT; PREGNANCY; PRENATAL DRUG EXPOSURE; PREVALENCE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TERATOGENICITY;

ABNORMALITIES, DRUG-INDUCED; CHILD, PRESCHOOL; FEMALE; GEORGIA; HUMANS; INFANT; INFANT, NEWBORN; LIMB DEFORMITIES, CONGENITAL; MATERNAL EXPOSURE; POISSON DISTRIBUTION; POPULATION SURVEILLANCE; PREGNANCY; PREVALENCE; RISK; THALIDOMIDE;

EID: 0030711513     PISSN: 01487299     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8628(19971219)73:3<251::AID-AJMG4>3.0.CO;2-V     Document Type: Article

References (44)

1. A EUEOCAT Working Group (1993): EUROCAT Report 5. Surveillance of congenital anomalies, 1980-1990. Brussels: EUROCAT Central Registry, Institute of Hygiene and Epidemiology, Ministry of Public Health and Environment.
2. Bod M, Czeizel A (1981): Congenital malformation surveillance. Teratology 24:277-283.
3. Burley D (1986): The decline and fall of thalidomide. In: Scheinberg IH, Walsh JM (eds): "Orphan Diseases and Orphan Drugs." London: Manchester University Press in association with the Fulbright Commission, pp 195-201.
4. Calzolari ED, Maservigi GP, Garani G, Cocchi C, Magnani, Milan M (1990): Limb reduction defects in Emillia Romagna, Italy: Epidemiologic and genetic study in 173,109 consecutive births. J Med Genet 27:353-357.
5. Castilla EE, Cavalcanti DP, Dutra MG, Lopes-Camelo JS, Paz JE, Gadow EC (1995): Limb reduction defects in South America. Br J Obstet Gynecol 102:393-400.
6. Castilla EE, Ashton-Prolla P, Barreda-Mejia E, Brunoni D, Cavalcanti DP, Correa-Neto J, Delgadillo JL, Dutra MG, Felix T, Giraldo A, Juarez N, Lopez-Camelo JS, Nazer J, Orioli IM, Paz JE, Pessoto MA, Pina-Neto JM, Quadrelli R, Rittler M, Rueda S, Saltos M, Sánchez O, Schüler L (1997): Thalidomide, a current teratogen in South America. Teratology 54:273-277.
7. Chen R (1979): Statistical techniques in birth defects surveillance systems. In: Klingberg MA, Weatherall JAC (eds): "Epidemiologic Methods for Detection of Teratogens." Basel/Munchen: Karger, pp 184-189.
8. Chen R (1985): Detection and investigation of subtle epidemics. Prog Clin Biol Res 163B:39-44.
9. Czeizel A (1973): The Hungarian congenital malformation register. Acta Univ Carol Med Monogr (Praha) 56:53-70.
10. D'Arcy PF, Griffin JP (1994): Thalidomide revisited. Adverse Drug React Toxicol Rev 13:65-76.
11. Edmonds LD, Layde PM, James LM, Flynt JD, Erickson JD, Oakley GP Jr (1981): Congenital malformations surveillance: Two American systems. Int J Epidemiol 10:247-252.
12. Erickson JD (1991): International Clearinghouse for Birth Defects Monitoring System: Past, present and future. Int J Risk Safety Med 2:239-248.
13. Erickson JD (1995): Thalidomide use on the rise. Teratol Soc News 5:5-6.
14. Flynt JW, Hay S (1979a): International clearinghouse for birth defects monitoring. Contr Epidemiol Biostat 1:44-52.
15. Flynt JW, Hay S (1979b): International clearinghouse for birth defects monitoring, in: Klingberg MA, Weatherall JAC (eds): "Epidemiologic Methods for Detection of Teratogens." Basel/Munchen: Karger, pp 44-52.
16. Gail M (1974): Power computations for designing comparative Poisson trials. Biometrics 30:231-237.
17. Hill GB, Spicer CC, Weatherall JAC (1968): The computer surveillance of congenital malformations. Br Med Bull 24:215-218.
18. Holtzman NA, Khoury MJ (1986): Monitoring for congenital malformations. Annu Rev Public Health 7:237-266.
19. International Clearinghouse for Birth Defects Monitoring Systems (1984) Limb reduction defects. In: "1982 Annual Report." Stockholm: Garnisonstryckeriet, pp 8-9.
20. James LM (1993): "Statistical Analysis Battery for Epidemiologic Research (SABER)." Atlanta: Centers for Disease Control and Prevention.
21. Jenkinson N (1993): Prescribing disaster. Belfast Telegraph. June 5, 1993, p. 9.
22. Källén B, Winberg J (1968): A Swedish register of congenital malformations. Pediatrics 41:765-776.
23. Källén B, Hay S, Klingberg M (1984a): Birth defect monitoring systems. In: Kalter H (eds): "Issues and Reviews in Teratology." New York: Plenum Publishing Corp., pp 1-22.
24. Källén B, Rahmani TMZ, Winberg J (1984b): Infants with congenital limb reduction registered in the Swedish register of congenital malformations. Teratology 29:73-85.
25. Kenett K, Pollak M (1983): On sequential detection of a shift in the probability of a rare event. J Am Stat Assoc 78:389-395.
26. Khoury MJ, Holtzman NA (1987): On the ability of birth defects monitoring to detect new teratogen. Am J Epidemiol 126:136-143.
27. Khoury MJ, Edmonds LD (1994): Metropolitan Atlanta Congenital Defects Program: Twenty-five years of birth defects surveillance at the Centers for Disease Control. Proceedings of III ASM International Symposium.
28. Klingberg MA, Papier CM, Hart J (1983): Birth defects monitoring. Am J Ind Med 4:309-328.
29. Lechat MF, De Wals P, Weatherall JAC (1985): European community's concerted action on congenital anomalies. Prog Clin Biol Res 163B:11-16.
30. Lechat MF, ed. (1989): "Eurocat Report: Surveillance of Congenital Anomalies, Years 1980-86. Brussels: Department of Epidemiology, Catholic University of Louvain.
31. Leck I (1979): Teratogenic risks of disease and therapy. Contr Epidemiol Biost 1:23-43.
32. Lenz W (1985): Thalidomide embryopathy in Germany, 1959-1961. In: Marois M (eds): "Prevention of Physical and Mental Congenital Defects. Part C: Basic and Medical Science, Education, and Future Strategies." New York: Liss, pp 77-84.
33. Lin S, Marshall EG, Davidson GK, Roth GB, Druschel CM (1993): Evaluation of congenital limb reduction defects in Upstate New York. Teratology 47:127-135.
34. Lubin JH, Gail M, Ershow AG (1988): Sample size and power for case-control studies when exposures are continuous. Stat Med 7:363-376.
35. Greenland S (1985): Power, sample size and smallest detectable effect determination for multivariate studies. Stat Med 4:117-127.
36. Lucas JM (1976): The design and use of cumulative sum quality control schemes. J Qual Technol 8:1-12.
37. Lucas JM (1982): Combined Shewhart-CUSUM quality control schemes. J Qual Technol 14:51-59.
38. Lucas JM (1985): Counted data CUSUM's. Technometrics 27:129-144.
39. Lynberg MC, Edmonds LD (1992): Surveillance of birth defects. In: Halperin W, Baker EL, Monson RR (eds): "Public Health Surveillance." New York: Van Nostrand Reinhold, pp 157-177.
40. Makonkawkeyoon S, Limson-Pobre EN, Moreira AL, Schauf V, Kaplan G (1993): Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 90:5974-5978.
41. Mitchell AA, Van Bennekom CM, Louik C (1995): A pregnancy-prevention program in women of childbearing age receiving isotretinion. N Engl J Med 333:101-106.
42. Oakley GP (1985): Birth defect epidemiology and surveillance. In: Marois M (eds): Prevention of physical and mental congenital defects. Part A: The scope of the problem. New York: Liss, pp 71-90.
43. Smithells RW, Newman CGH (1992): Recognition of thalidomide defects (syndrome of the month). J Med Genet 29:716-723.
44. Yang MCK (1978): Determination of sample size for testing the relation between an incidence and a set of random variables in a sample survey. Biometrika 65:635-640.